City Therapeutics is a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines for a range of diseases.
City Therapeutics has raised $99.5M in total funding. The most recent round was Series B. The last funding was announced in June 2026.
City Therapeutics's investors include ARCH Venture Partners, Fidelity, Sofinnova Investments, Invus, AN Ventures.
City Therapeutics is headquartered in Cambridge, United States.
City Therapeutics is a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines for a range of diseases.
City Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"City Therapeutics — Funding & Investors." VCBacked, June 8, 2026, https://www.vcbacked.co/company/city-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). City Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/city-therapeutics
{{cite web |title=City Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/city-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated